DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
RAF-265 is an investigational drug.
There have been 237 clinical trials for RAF-265. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2014.
The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Bayer, and Novartis Pharmaceuticals.
There are three hundred and sixty-five US patents protecting this investigational drug and three international patents.
Recent Clinical Trials for RAF-265
|A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.||Deciphera Pharmaceuticals LLC||Phase 1|
|A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma||Pacific Pediatric Neuro-Oncology Consortium||Phase 2|
|A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma||Day One Biopharmaceuticals, Inc.||Phase 2|
Top disease conditions for RAF-265
Top clinical trial sponsors for RAF-265
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|RAF-265||Get Started Free||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||Get Started Free|
|RAF-265||Get Started Free||Small molecule HSP70 inhibitors||The Trustees of the University of Pennsylvania (Philadelphia, PA) The Wistar Institute of Anatomy and Biology (Philadelphia, PA)||Get Started Free|
|RAF-265||Get Started Free||Compounds and compositions as inhibitors of MEK||Novartis AG (Basel, CH)||Get Started Free|
|RAF-265||Get Started Free||Methods for treatment of melanoma||CHILDREN'S MEDICAL CENTER CORPORATION (Boston, MA) DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|RAF-265||Australia||AU2014348657||2033-11-13||Get Started Free|
|RAF-265||Australia||AU2017245411||2033-11-13||Get Started Free|
|RAF-265||Australia||AU2019246853||2033-11-13||Get Started Free|
|RAF-265||Brazil||BR112016010716||2033-11-13||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|